IP Library Granted Patent US 8,377,048
Granted Patent B2
US 8,377,048 · App. 12/349,257 · Granted Feb 19, 2013

Minimizing the side-effects of refractive corrections using statistically determined irregularities in intrastromal incisions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,048
App. No.
12/349,257
Granted
Feb 19, 2013
Kind
B2
Abstract

A system and method for minimizing adverse visual effects that may be introduced during laser refractive surgery, requires making laser incisions into stromal tissue in a predetermined manner. Specifically, a plurality of irregular incisions are statistically distributed in the stroma in a manner that causes them to be visually elusive, and thereby minimize their adverse visual effects. The incisions must, however, still accomplish their intended surgical purpose of weakening the stroma in a predetermined manner. To do this, each irregular incision has a width of arc length dθ m , a length dz l and a characteristic radial distance dr n from the visual axis of the eye. Values for dθ m , dz l and dr n are established using a random number generator.

Claims (23)

1. A method for minimizing visual side-effects of a refractive surgical procedure which comprises the steps of:

identifying a change for biomechanical stresses within a stroma of an eye, wherein the change is necessary to affect a defined optical correction;

determining a statistical distribution for structural alterations in the stroma to implement the change;

creating a plurality of unique irregular incisions manifesting the structural alterations in the stroma to accomplish the optical correction;

locating each irregular incision in accordance with the statistical distribution to cause the plurality of irregular incisions to become visually elusive for minimizing the visual side-effects of the surgical procedure while achieving the defined optical correction; and

wherein the eye defines a visual axis and has an anterior surface, and wherein each irregular incision is defined by a length dz l measured along a line perpendicular to the anterior surface and by an arc width dθ m measured along an azimuthal arc centered on the visual axis, and further wherein each irregular incision is located at a radial distance dr n from the visual axis.

2. A method as recited in claim 1 wherein each arc width dθ m is in a range between approximately 8° and 12°, wherein m =1→36, and wherein Σdθ m =360°.

3. A method as recited in claim 2 wherein each irregular incision having a same dθ m has a same dz l +an overlap Δ, wherein l=1→10, wherein each dz l is in a range of 30 μm to 50 μm, and further wherein Δ<approximately 10 μm.

4. A method as recited in claim 3 wherein each irregular incision having a same dθ m is located by said radial distance dr n , wherein n=1→5, dr 1 >1 mm and Σdr n <approximately 2 mm.

5. A method as recited in claim 4 wherein the distance dr n for an irregular incision in a dθ m is established to be within a respective predetermined radial distance of other irregular incisions with a same dr n in dθ m+1 and in dθ m−1 .

6. A method as recited in claim 4 wherein the distance between dr n and dr n+1 within a same dθ m is greater than approximately 50 μm.

7. A method as recited in claim 4 wherein values for dθ m , dz l and dr n are established by using a random number generator.

8. A method as recited in claim 4 wherein dr n is a radial extension of dr n+1 .

9. A method as recited in claim 1 wherein the irregular incisions of dθ m are axially symmetric with the irregular incision of dθ m +180°.

10. A method for creating a pattern of irregular incisions in the stroma of an eye to correct a vision defect, with minimal resulting visual side effects, the method comprising the steps of:

defining each irregular incision in the pattern relative to a geometry of the eye, wherein the eye geometry includes a visual axis and an anterior surface, and each irregular incision has an arc width dθ m measured along an azimuthal arc centered on the visual axis, with a length dz l plus an overlap Δ measured along a line substantially perpendicular to the anterior surface of the eye;

locating each irregular incision within a same dθ m using a characteristic radial distance dr n ; and

using a random number generator to establish values for dθ m , dz l and dr n .

11. A method as recited in claim 10 wherein each arc width dθ m is in a range between approximately 8° and 12°, where m =1→36 and Σdθ m =360°, wherein l=1→10 and each dz l is in a range of 30 μm to 50 μm with Δless than approximately 10 μm, and further wherein n =1→5 with dr 1 greater than approximately 1 mm and Σdr n less than approximately 2 mm.

12. A method as recited in claim 10 wherein dr n and dz l of dθ m is the same as the respective dr n and dz l of dθ m +180°.

13. A method as recited in claim 12 wherein m=1→18 and Σdθ m =180°.

14. A method as recited in claim 10 wherein the distance dr n for an irregular incision in a dθ m is established to be within a respective predetermined radial distance of other irregular incisions with a same dr n in dθ m+1 and in dθ m−1 .

15. A method as recited in claim 14 wherein the distance between dr n and dr n+1 within a same dθ m is greater than approximately 50 μm.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →